Analysis of Congenital Heart Diseases Market

Congenital heart disease (COHD) is a heart condition resulting from an abnormality in heart structure or function that is present at birth. Some common congenital heart defects include Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Left Atrial Appendage (LAA) and Patent Ductus Arteriosus (PDA). Ventricular Septal Defects (VSD) is the most common type of congenital heart defects in newborns. The Centre for Disease and Control (CDC) estimates that about 42 out of every 10,000 babies are born with VSD in the United States.

Most congenital heart diseases are diagnosed in babies (aged under a year), 30% in children (aged 1-15 years), and 10% in adulthood (16 years and over). The increasing number of addressable patients for congenital heart defects in the U.S, Europe and Japan is a potential opportunity for this market. In addition, the mortality rate attributable to congenital defects has been declining over the last few years.

Rise in survival rates of COHD patients till adulthood, evolution of new diagnostic techniques, increasing consumer income and rising number of cardiologists and medical practitioners are the main factors that will be driving the market in future.

The congenital heart defect market is characterized by few competitors due to high entry barriers. AGA Medical is the market leader in the structural heart repair market. The other major players include NMT Medical, St. Jude medical, GORE Medical, Occlutech and Coherex.

The current report analyzes the market size and segmentation of the congenital heart diseases market. The various drivers, opportunities and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.